scholarly journals Effect of Baseline Disease Severity on Achievement of Treatment Target With Apremilast: Results From a Pooled Analysis

2021 ◽  
Author(s):  
K. Reich ◽  
U. Mrowietz ◽  
A. Menter ◽  
C.E.M. Griffiths ◽  
J. Bagel ◽  
...  
Keyword(s):  
Disease Severity ◽  
Pooled Analysis ◽  
Treatment Target ◽  
Baseline Disease Severity

scholarly journals P376 Real life health care utilisation in paediatric patients with inflammatory bowel disease in the era of biologics

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S354-S354
Author(s):  
S A Tchogna ◽  
X Y Yang ◽  
C Deslandres ◽  
P Jantchou
Keyword(s):  
Health Care ◽  
Disease Severity ◽  
Health Care Services ◽  
Activity Index ◽  
Healthcare Utilisation ◽  
Adult Care ◽  
Care Services ◽  
Inflammatory Bowel ◽  
Baseline Disease Severity

Abstract Background The burden associated with the management of paediatric patients with inflammatory bowel disease (IBD) has been rising as the incidence of IBD is increasing in children. In addition, the widespread use of biologics and a treat-to-target approach also contributes to the increase of healthcare utilisation. Methods The purpose of this study was to assess the health care services utilisation and the associated factors in a prospective cohort of children diagnosed with IBD in Quebec, Canada. Patients diagnosed from 2013 to 2015 and followed up until the transfer to adult care were identified in our IBD database. Data on IBD related services and treatments: imaging procedures, hospitalisations and outpatient visits, medications from diagnosis to transition was extracted. We analyzed the healthcare utilisation according to the baseline disease severity (paediatric Crohn’s disease activity index or paediatric ulcerative colitis activity index) at diagnosis, and according to exposition to intravenous biologics. Results In total, 144 patients were included in the study [(77 males), CD (N = 98), UC (N = 31) and IBD-U (N = 15); median (interquartile(IQR)) age at diagnosis 15.2 (14.3–16.3) years]. The median (IQR) duration of paediatric follow-up was 2.9 (1.8–3.9) years. The median (min-max) number of imaging procedures varied largely: esophagogastroduodenoscopy 1(0–2), colonoscopy 1(1–6), abdominal ultrasound1(0–13), abdominal MRI 1(0–4), tomodensitometry 0(0–2), bone densitometry 1(0–5). Patients had various follow-up encounters (median(min–max)): outpatient visits 9(1–28), IBD nurses phone follow-ups 4(0–33). Sixty-four per cent of patients had at least one hospitalisation [median(min–max)1(0–10); median duration 4(0–150 days)] and 35.41% had at least one emergency visit. Baseline disease severity did not predict the disease burden: the mean number of encounters was 3.0/year in the moderate/severe group as compared with 2.5/year in the mild group; p = 0.61. Among the, 63.5% of patients exposed to an intravenous biologic (Infliximab or Vedolizumab), those exposed earlier (<3 months after diagnosis) used more health care services (mean = 3.3/year) than those exposed later (mean = 2.23/year); p <0.0001. In addition, the median (IQR) cumulative days of healthcare utilisation (missing school days) for patients treated with intravenous biologics was 48.5(32.4–67.9) days during paediatric care. Conclusion Adolescents with IBD have several healthcare encounters between the diagnosis and transfer to adult care. Disease severity at diagnosis was not related to a higher level of health services utilisation during follow-up. However, treatment with intravenous biologics was associated with a high health service utilisation and school missing during follow-up.

Improving COPD symptoms with umeclidinium/vilanterol and impact of baseline disease severity: the EMAX trial

2019 ◽  
Author(s):  
François Maltais ◽  
Claus F. Vogelmeier ◽  
Isabelle H. Boucot ◽  
Leif Bjermer ◽  
Edward M. Kerwin ◽  
...  
Keyword(s):  
Disease Severity ◽  
Baseline Disease Severity

Mo1219 Adalimumab Achieves Efficacy in Mucosal Healing Regardless of Baseline Disease Severity in Patients With Crohn's Disease: Data From EXTEND

2014 ◽  
Vol 146 (5) ◽  
pp. S-589
Author(s):  
William Sandborn ◽  
Douglas C. Wolf ◽  
Jean-Frederic Colombel ◽  
Julian Panes ◽  
Samantha Eichner ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Disease Severity ◽  
Mucosal Healing ◽  
Baseline Disease Severity

scholarly journals Evaluation of maize genotypes for Turcicum leaf blight (Exserohilum turcicum) in Terai and inner terai of Nepal

2016 ◽  
Vol 2 (1) ◽  
pp. 109-116
Author(s):  
Tirtha Raj Rijal ◽  
Govind KC ◽  
Kesab Babu Koirala ◽  
Jiban Shrestha
Keyword(s):  
Disease Severity ◽  
Pooled Analysis ◽  
Leaf Blight ◽  
Exserohilum Turcicum ◽  
Sources Of Resistance ◽  
Maize Productivity ◽  
Maize Genotypes ◽  
Disease Severity Scale ◽  
High Yielding Varieties ◽  
Moderately Resistant

Thirty maize genotypes in 2014-2015 at Dumarwana, Nijgadh, Keureni and Rampur and ten genotypes in 2015-2016 at Anandpur, Shitalnagar, Dumarwana, Nijgadh and Rampur were evaluated for resistance to Turcicum leaf blight (Exserohilum turcicum) under farmers field conditions. The scale used for disease severity ranged from 1-5 scale based on the proportionate leaf area affected by the disease. The combined analysis over locations in 2014-2015 showed that among the 30 genotypes 25 genotypes were resistant (1.0-2.0 scale), and 5 genotypes were moderately resistant (2.1-3.0 scale). Similarly the pooled analysis over locations in 2015-2016 showed that 7 genotypes were resistant (1.0-2.0 scale) and 3 genotypes were moderately resistant (2.1-3.0 scale). The maize genotypes namely Z376-26, Z478-3, Z433-99, Z464-5, Z478-2, Z466-1, CAH1513, RML-95/RML-96, CAH1515, CAH1521, CAH1515, CAH151, CAH153, ZH114228 , Z376-9, Z466-3, Z376-5, RML-32/RML-17, RML-86/RML-96 and 900MGold were resistant with disease severity scale of 1.5 and with higher grain yield in both the years. Thus above genotypes were identified as promising sources of resistance against E. turcicum and they can be used to develop disease resistant and high yielding varieties to enhance maize productivity in terai and inner terai of Nepal.

Sign in / Sign up

Export Citation Format

Share Document